We are live on ! Find out more
CTOR icon

Citius Oncology
CTOR

7 hedge funds and large institutions have $57K invested in Citius Oncology in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

43.13% less ownership

Funds ownership: 43.19% → 0.06% (-43%)

46% less funds holding

Funds holding: 13 → 7 (-6)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

100% less capital inflows, than outflows

Capital inflows: $109K | Capital outflows: $42.5M

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-6
Holders Change %
-46.15%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
2
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IFP Advisors
IFP Advisors
Florida
+$57.7K
2
Osaic Holdings
Osaic Holdings
Arizona
+$38.9K
3
UBS Group
UBS Group
Switzerland
+$11.6K
4
Bank of America
Bank of America
North Carolina
+$1.14K

Top Sellers

Rank Fund Capital Flow
1
Cowen and Company
Cowen and Company
New York
-$7.12M
2
W.R. Berkley Corp
W.R. Berkley Corp
Connecticut
-$6.02M
3
Wolverine Asset Management
Wolverine Asset Management
Illinois
-$4.62M
4
Rivernorth Capital Management
Rivernorth Capital Management
Florida
-$3.98M
5
Mizuho Securities USA
Mizuho Securities USA
New York
-$3.86M

CTOR Hedge Fund Activity: Q3 2024 in Review

7 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q3 2024, worth a combined $57K — down 100% from $43.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CTOR and 4 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was IFP Advisors, opening a new position worth an estimated $57.7K. The largest seller was Cowen and Company, exiting entirely with an estimated $7.12M sold.

  • 7 institutional investors held Citius Oncology (CTOR) as of Q3 2024, down from 13 in Q2 2024.
  • Funds reported $57K of Citius Oncology stock for Q3 2024, down 100% quarter-over-quarter.
  • 4 funds opened new Citius Oncology positions in Q3 2024 and 10 closed out, a net change of -6 holders.
  • The largest Citius Oncology buyer in Q3 2024 was IFP Advisors, an estimated $57.7K added.
  • The largest Citius Oncology seller in Q3 2024 was Cowen and Company, an estimated $7.12M sold.

Based on aggregated 13F filings for Q3 2024.